GlassScriptPhysician profile
Jacob Whitney
NPI 1770119083
$12,532.74
in general payments reported to CMS, 2019-2025
63 companies · $14.19 in 2025
The $14.19 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,147 · 2022: $1,346 · 2023: $5,126 · 2024: $1,899 · 2025: $14.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,039.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,735.10 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $977.74 | 2021-2024 | |
| Ucb, INC. | $930.09 | 2021-2024 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $840.08 | 2021-2024 | Amyvid, Emgality, Reyvow |
| Biogen, INC. | $667.42 | 2021-2024 | Vumerity, Tysabri, Skyclarys |
| Allergan, INC. | $531.15 | 2021-2022 | |
| Csl Behring | $447.82 | 2021-2024 | Hizentra, Privigen |
| Alexion Pharmaceuticals, INC. | $444.91 | 2021-2024 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $444.79 | 2021-2023 | Austedo Xr, Austedo, Ajovy |
| Amgen INC. | $425.29 | 2021-2023 | Aimovig |
| Pfizer INC. | $407.42 | 2023-2024 | |
| Kyowa Kirin, INC. | $324.84 | 2021-2023 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $299.72 | 2021 | |
| Lundbeck LLC | $289.77 | 2021-2024 | Vyepti, Rexulti |
| Eisai INC. | $287.38 | 2023-2024 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.